论文部分内容阅读
应用免疫调节分子增强抗肿瘤免疫反应是治疗癌症的新策略。CD137介导的信号通路是一重要的共刺激途径。CD137属于肿瘤坏死因子受体超家族成员,表达在活化的T细胞、自然杀伤细胞、单核细胞表面,通过连接其天然配体CD137L或用CD137激动性单克隆抗体激活CD137,既能提供共刺激信号激活T细胞,使T细胞活化增殖并分泌细胞因子,同时它介导的反向共刺激信号诱导抗原提呈细胞(antigenpresetingcell,APC)增殖并分泌细胞因子。动物实验表明,干预CD137共刺激途径可调节T细胞和APC的功能产生抗肿瘤免疫作用,单独干预CD137共刺激途径或与其他治疗方式联用将成为肿瘤免疫治疗的新方式。
Application of immunomodulatory molecules to enhance anti-tumor immune response is a new strategy for the treatment of cancer. CD137-mediated signaling is an important costimulatory pathway. CD137, a member of the tumor necrosis factor receptor superfamily, is expressed on activated T cells, natural killer cells, and monocytes by either co-stimulating CD137L with its native ligand CD137L or CD137 with a CD137 agonist monoclonal antibody, Signaling activates T cells, activates T cells to proliferate and secrete cytokines, and at the same time it mediates reverse costimulation signals to induce the proliferation of antigen-presenting cells (APCs) and to secrete cytokines. Animal experiments show that intervening CD137 costimulatory pathway can regulate the function of T cells and APCs to produce antitumor immunity. Intervention with CD137 alone or in combination with other treatments will be a new way of tumor immunotherapy.